NQO-1 Antibody (A180)

Flow Cytometry: NQO-1 Antibody (A180) [NB200-209]

Flow Cytometry: NQO-1 Antibody (A180) [NB200-209] - An intracellular stain was performed on U-87 cells with NQO-1 [A180] Antibody NB200-209AF647 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 647.

Western Blot: NQO-1 Antibody (A180) [NB200-209]

Western Blot: NQO-1 Antibody (A180) [NB200-209] - Detection of NQO1 in A549 lysates using NB 200-209. Lane 1: 0.5 ug/ml. Lane 2: 2 ug/ml. Exposure: 1 second.

Immunohistochemistry-Paraffin: NQO-1 Antibody (A180) [NB200-209]

Immunohistochemistry-Paraffin: NQO-1 Antibody (A180) [NB200-209] - Immunohistochemistry showing Anti-NQ01 on formalin fixed paraffin embedded human kidney tissue

Flow (Intracellular): NQO-1 Antibody (A180) [NB200-209]

Flow (Intracellular): NQO-1 Antibody (A180) [NB200-209] - An intracellular stain was performed on U87MG cells with NQO1 (A180) antibody NBP2-24917 (blue) along with a matched isotype control NBP2-27287 (orange). Cells were fixed with 4% PFA and permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 1 ug/mL for 30 minutes at room temperature, followed by mouse F(ab)2 IgG (H+L) APC-conjugated secondary antibody (F0101B, R&D Systems).

Flow Cytometry: NQO-1 Antibody (A180) [NB200-209]

Flow Cytometry: NQO-1 Antibody (A180) [NB200-209] - Detection of NQO-1 in Human A549 Cell Line by Flow Cytometry. Human A549 cell line was stained with Mouse Anti- NQO-1 Monoclonal Antibody (Catalog # NB200-209, filled histogram), or Mouse IgG1 isotype control (Catalog # MAB002, open histogram) followed by APC-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # F0101B). To facilitate intracellular staining, cells were fixed with FlowX FoxP3 Fixation & Permeabilization Buffer Kit (Catalog # FC012).
Images may not be copied, printed or otherwise disseminated without express written permission of Novus Biologicals a bio-techne brand.

Flow Cytometry: NQO-1 Antibody (A180) [NB200-209]

Flow Cytometry: NQO-1 Antibody (A180) [NB200-209] - An intracellular stain was performed on U-87 cells with NQO-1 [A180] Antibody NB200-209C (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to DyLight 650.

Simple Western: NQO-1 Antibody (A180) [NB200-209]

Simple Western: NQO-1 Antibody (A180) [NB200-209] - Simple Western lane view shows a specific band for NQO-1 in 0.5 mg/ml of A431 lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.

Western Blot: NQO-1 Antibody (A180) [NB200-209] -

Western Blot: NQO-1 Antibody (A180) [NB200-209] - Antioxidant enzyme synthesis in response to orange oil treatment. Immunoblot analysis demonstrating expression of HO-1, NQO1 & GCLm proteins at 6, 12 & 24 hrs following 15 min treatment of BEAS-2B cells with the oil preparation or time-matched soy oil control. Representative blots from one of three separate experiments are shown above. Densitometric evaluations of each target protein blot normalized to its corresponding GAPDH for all three experiments are provided below. Bars represent mean ± SEM. Image collected & cropped by CiteAb from the following publication (https://respiratory-research.biomedcentral.com/articles/10.1186/1465-9921-12-92), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: NQO-1 Antibody (A180) [NB200-209] -

Western Blot: NQO-1 Antibody (A180) [NB200-209] - Equol attenuated ER stress by activating Nrf2 in vitro & in vivo.(A) HUVECs were incubated with different concentrations (1, 10 & 100 nM) of equol for 24 h before treatment with t-BHP (50 μM) for another 6 h. The expression of Nrf2 & NQO1 was detected by western blotting. (C) Total tissue lysates from the thoracic & abdominal aorta of apoE-/- mice with or without equol treatment were immunoblotted with anti-Nrf2 & anti-beta -actin antibodies. (E) Cells were transfected with Nrf2 siRNA for 5~6 h; the medium was then replaced with fresh culture medium, followed by incubation for another 24 h. Thereafter, the cells were treated with equol (100 nM) for 24 h & then were incubated with t-BHP (50 μM) for an additional 6 h. The cells were collected & lysed, & western blot analysis was performed. (B)(D)(F) The bar charts show the quantification of the indicated proteins. (G) HUVECs were transfected with Nrf2 siRNA & treated as described in (C), & cell apoptosis was assayed using the Cell Death Detection ELISAplus Kit. Values are presented as means ± SD. n = 3, *p < 0.05, **p < 0.01, ***p < 0.001 versus the control group, RC group or siRNA treated with no drug group; #p < 0.01, ##p < 0.001 versus the t-BHP-treated group & siRNA plus t-BHP treated group. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/27907038), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: NQO-1 Antibody (A180) [NB200-209] -

Western Blot: NQO-1 Antibody (A180) [NB200-209] - S-(-)equol primarily up-regulated Nrf2 protein expression activating ARE-dependent response.(A) Whole EA.hy926 cells lysates of cells treated with 250 nM S-(-)equol, 500 nM daidzein, or 50 µM tBHQ for 24 h were subjected to immunoblot analysis with anti-Nrf2, anti-HO-1, anti-NQO1, & anti-beta -tubulin antibodies. (B) Total HUVECs lysates of cell treated with 250 nM S-(-)equol for 24 h were immunoblotted with anti-Nrf2 & anti-beta -tubulin antibodies. (C) EA.hy926 cells were transfected with plasmids containing an HA-tagged Nrf2 open reading frame & the renilla firefly luciferase gene. Medium was changed after 6 hours of incubation. Where indicated, extracts from HA-Nrf2 EA hy.92 cells were additionally probed with anti-HA antibody, anti-Nrf2, anti-HO-1, anti-NQO1 & anti-beta -tubulin antibodies. Values are means of three independent experiments with standard deviations represented by vertical bars. Mean values were significantly different compared to controls (*p<0.05). Total RNA was extracted from EA.hy926 cells or HUVECs treated as indicated, & Nrf2 (D), HO-1 (E), & NQO1 (F) mRNA was measured by real-time RT-PCR analysis. The values shown represent the mean ± SD obtained for three independent experiments (*p<0.05). Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/24260155), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: NQO-1 Antibody (A180) [NB200-209] -

Western Blot: NQO-1 Antibody (A180) [NB200-209] - S-(-)equol primarily up-regulated Nrf2 protein expression activating ARE-dependent response.(A) Whole EA.hy926 cells lysates of cells treated with 250 nM S-(-)equol, 500 nM daidzein, or 50 µM tBHQ for 24 h were subjected to immunoblot analysis with anti-Nrf2, anti-HO-1, anti-NQO1, & anti-beta -tubulin antibodies. (B) Total HUVECs lysates of cell treated with 250 nM S-(-)equol for 24 h were immunoblotted with anti-Nrf2 & anti-beta -tubulin antibodies. (C) EA.hy926 cells were transfected with plasmids containing an HA-tagged Nrf2 open reading frame & the renilla firefly luciferase gene. Medium was changed after 6 hours of incubation. Where indicated, extracts from HA-Nrf2 EA hy.92 cells were additionally probed with anti-HA antibody, anti-Nrf2, anti-HO-1, anti-NQO1 & anti-beta -tubulin antibodies. Values are means of three independent experiments with standard deviations represented by vertical bars. Mean values were significantly different compared to controls (*p<0.05). Total RNA was extracted from EA.hy926 cells or HUVECs treated as indicated, & Nrf2 (D), HO-1 (E), & NQO1 (F) mRNA was measured by real-time RT-PCR analysis. The values shown represent the mean ± SD obtained for three independent experiments (*p<0.05). Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/24260155), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: NQO-1 Antibody (A180) [NB200-209] -

Western Blot: NQO-1 Antibody (A180) [NB200-209] - Phf2 protects the liver from high fat & high sucrose diet-induced fibrogenesis during obesity. GFP or Phf2 were overexpressed through AAV strategy specifically in the liver of 7-week-old male C57Bl/6 J mice. Mice were then fed with either a chow diet (NCD) or with a high fat & high sucrose diet (HFHSD) for 16 weeks. Mice were studied in the fed state. a Representative western blot analysis showing the contribution of Phf2 overexpression to the regulation of the PI3K/Akt signaling & pro-fibrogenic pathways in liver extracts (n = 15 per group). b (Left) Oral glucose tolerance test & insulin levels during the OGTT test. (right) Insulin tolerance test (n = 15 per group). c Liver sections stained with hematoxylin & eosin (H&E), trichrome masson & sirius red are shown. Scale bars = 100 μm (n = 10 per group). d Percentage of fibrotic area & percentage of apoptotic hepatocytes (n = 15 per group). e Relative oxidized GSSG content & measurement of Gpx activity (n = 10 per group). f Levels of carbonylated proteins (n = 10 mice per group). All error bars represent mean ± SEM. Statistical analyses were made using unpaired t-test (b) or Anova, followed by Bonferonni’s test (d, e). *P < 0.01 HFHSD/GFP compared to HFHSD/Phf2, $P < 0.01 HFHSD/GFP compared to NCD/GFP, £P < 0.01 HFHSD/Phf2 compared to HFHSD/GFP Image collected & cropped by CiteAb from the following publication (https://www.nature.com/articles/s41467-018-04361-y), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: NQO-1 Antibody (A180) [NB200-209] -

Western Blot: NQO-1 Antibody (A180) [NB200-209] - Activation of Nrf2 signaling pathway by FST in RAW 264.7 mouse macrophage-like cells. Cells were treated with FST with or without 100 ng/mL RANKL for 5 days. (A) Total cellular proteins were isolated from cells & the expression levels of Nrf2 & its regulatory proteins were assessed by Western blot analysis. beta-actin was used as the internal control. (C) The expression of nuclear & cytosol Nrf2 were determined by Western blotting. Lamin B & beta-actin were used as internal controls for the nuclear & cytosolic fractions, respectively. The results shown are representative of three independent experiments. (B,D) Statistical analyses were conducted using analysis of variances between groups. * p < 0.05 & *** p < 0.0001 when compared to control. # p < 0.05 & ### p < 0.0001 when compared to RANKL treatment. RANKL: receptor of activator of nuclear factor kappa-B ligand; FST: fermented sea tangle extract; Nrf2: nuclear factor-erythroid 2-related factor 2; p-Nrf2: phosphorylated nuclear factor-erythroid 2-related factor 2; HO-1: heme oxygenase-1; NQO-1: NAD(P)H quinone oxidoreductase 1; +: cells treated the reagent; -: cells untreated the reagent. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/31357503), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: NQO-1 Antibody (A180) [NB200-209] -

Western Blot: NQO-1 Antibody (A180) [NB200-209] - Nrf2-pathway activation by hybrids: nuclear translocation & targets induction. (A) Nuclear cellular extracts of SH-SY5Y cells were treated for 3 hours with compounds at 5 µM, 500 nM, & 50 nM or with 20, 10, & 5 µM dimethyl fumarate (DMF). Nrf2 protein content in the nucleus was determined by Western blot. Anti-lamin A/C was used as a protein loading control. Results are shown as ratio Nrf2/lamin A/C ± SEM; *p < 0.05, **p < 0.01 & ****p < 0.0001 versus CTR; Dunnett’s multiple comparison test (F ratio = 6.797, n≥3). (B–C) RNA from total cellular extracts of SH-SY5Y cells, treated for 24 hours with 5 μM compounds or 20 μM DMF, were analyzed for NQO1 (B) & HO-1 (C) mRNA expression by RT-qPCR. GAPDH was used as housekeeping gene. Results are shown as mean ± SEM; *p < 0.05, **p < 0.01, & ***p < 0.001 versus CTR; Dunnett’s multiple comparison test (B, n≥3, F ratio = 10.44; C, n≥3, F ratio = 13.95). (D–E) Cellular extracts of SH-SY5Y cells treated for 24 hours with compounds at 5 μM or 20 μM DMF were analyzed for NQO1 (D) & HO-1 (E) protein levels by Western blot. Anti-actin was used as protein loading control. Results are shown as ratio (% of CTR) ± SEM; *p < 0.05, **p < 0.01, ***p < 0.001, & ****p < 0.0001 versus CTR; Dunnett’s multiple comparison test (D, n ≥ 3, F ratio = 5.144; E, n≥3, F ratio = 17.26). Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/32047434), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: NQO-1 Antibody (A180) [NB200-209] -

Western Blot: NQO-1 Antibody (A180) [NB200-209] - The effects of PI3K/Akt & ER inhibitors on S-(-)equol-induced Nrf2 activation in endothelial cells.(A) EA.hy926 cells or HUVECs transfected w/ ARE-dependent firefly luciferase reporter gene (F) & the renilla firefly luciferase gene (R), & treated w/ 250 nM S-(-)equol in the presence or absence of 10 µM LY294002 or 100 nM ICI182,780 for 16 h. The potency of induction is expressed as the relative luminescence (R/F) measured using the dual luciferase reporter assay system (mean ± SD, n = 3). *p<0.05 versus w/ control group, #p<0.05 versus w/ S-(-)equol treated group. (B) EA.hy926 cells or HUVECs incubated w/ or w/out 10 µM LY294002 or 100 nM ICI182,780 for 30 min & then w/ or w/out 250 nM S-(-)equol or 500 nM daidzein for 24 h. Whole cell lysates then immunoblotted w/ antibodies against Nrf2, HO-1, NQO1, & beta-tubulin. Values are means of three independent experiments w/ standard deviations represented by vertical bars. Mean values significantly different compared w/ controls (*p<0.05). (C) EA.hy926 cells or HUVECs cotransfected w/ the HA-Nrf2 & renilla firefly luciferase expression plasmids treated w/ 250 nM S-(-)equol in the presence or absence of 10 µM LY294002 or 100 nM ICI182,780 for 16 h, & HA-Nrf2 localization analyzed by confocal microscopy. (D) EA.hy926 cells incubated w/ 250 nM S-(-)equol, 500 nM daidzein w/ or w/out 10 µM LY294002 or 100 nM ICI182,780 for 16 h & then immunostained w/ an antibody against Nrf2, & Nrf2 localization analyzed by confocal microscopy. Values (intensity of nuclear versus cytoplasmic) are means of counting 100 cells w/ standard deviations represented by vertical bars. *p<0.05 versus w/ control group, #p<0.05 versus w/ S-(-)equol treated group. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/24260155), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: NQO-1 Antibody (A180) [NB200-209] -

Western Blot: NQO-1 Antibody (A180) [NB200-209] - S-(-)equol primarily up-regulated Nrf2 protein expression activating ARE-dependent response.(A) Whole EA.hy926 cells lysates of cells treated with 250 nM S-(-)equol, 500 nM daidzein, or 50 µM tBHQ for 24 h were subjected to immunoblot analysis with anti-Nrf2, anti-HO-1, anti-NQO1, & anti-beta -tubulin antibodies. (B) Total HUVECs lysates of cell treated with 250 nM S-(-)equol for 24 h were immunoblotted with anti-Nrf2 & anti-beta -tubulin antibodies. (C) EA.hy926 cells were transfected with plasmids containing an HA-tagged Nrf2 open reading frame & the renilla firefly luciferase gene. Medium was changed after 6 hours of incubation. Where indicated, extracts from HA-Nrf2 EA hy.92 cells were additionally probed with anti-HA antibody, anti-Nrf2, anti-HO-1, anti-NQO1 & anti-beta -tubulin antibodies. Values are means of three independent experiments with standard deviations represented by vertical bars. Mean values were significantly different compared to controls (*p<0.05). Total RNA was extracted from EA.hy926 cells or HUVECs treated as indicated, & Nrf2 (D), HO-1 (E), & NQO1 (F) mRNA was measured by real-time RT-PCR analysis. The values shown represent the mean ± SD obtained for three independent experiments (*p<0.05). Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/24260155), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: NQO-1 Antibody (A180) [NB200-209] -

Western Blot: NQO-1 Antibody (A180) [NB200-209] - Activation of Nrf2 signaling pathway by FST in RAW 264.7 mouse macrophage-like cells. Cells were treated with FST with or without 100 ng/mL RANKL for 5 days. (A) Total cellular proteins were isolated from cells & the expression levels of Nrf2 & its regulatory proteins were assessed by Western blot analysis. beta-actin was used as the internal control. (C) The expression of nuclear & cytosol Nrf2 were determined by Western blotting. Lamin B & beta-actin were used as internal controls for the nuclear & cytosolic fractions, respectively. The results shown are representative of three independent experiments. (B,D) Statistical analyses were conducted using analysis of variances between groups. * p < 0.05 & *** p < 0.0001 when compared to control. # p < 0.05 & ### p < 0.0001 when compared to RANKL treatment. RANKL: receptor of activator of nuclear factor kappa-B ligand; FST: fermented sea tangle extract; Nrf2: nuclear factor-erythroid 2-related factor 2; p-Nrf2: phosphorylated nuclear factor-erythroid 2-related factor 2; HO-1: heme oxygenase-1; NQO-1: NAD(P)H quinone oxidoreductase 1; +: cells treated the reagent; -: cells untreated the reagent. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/31357503), licensed under a CC-BY license. Not internally tested by Novus Biologicals.